Beyond the Distinction Between Biomedical and Social Dimensions of HIV Prevention Through the Lens of a Social Public Health

Overview

Journal Am J Public Health

Specialty Public Health

Date 2012 Apr 13

PMID 22493997

Citations 48

Authors

Susan Kippax

Niamh Stephenson

Affiliations

Soon will be listed here.

Abstract

Developing effective HIV prevention requires that we move beyond the historical but problematic distinction between biomedical and social dimensions of HIV. The current claim that prevention has failed has led to a strong interest in the role of treatment as HIV prevention; however, the turn to "biomedical prevention," "test and treat," and "combination prevention" instances pervasive confusions about prevention. These confusions arise from a failure to realize that all HIV prevention interventions must engage with the everyday lives of people and be integrated into their social relations and social practices. We challenge the claim that prevention has failed (illustrating this with discussion of prevention in Australia, Uganda, and Zimbabwe). We explain the enduring appeal of misguided approaches to prevention by examining how 1996 can be seen as a pivotal moment in the history of the global response to HIV, a moment marked by the rise and fall of distinct biomedical and social narratives of HIV.

Citing Articles

Protocol for a systematic search and critical discourse analysis of research on national HIV pre-exposure prophylaxis programmes among gay, bisexual, and other men who have sex with men.

Comer D, Noone C HRB Open Res. 2024; 7:12.

PMID: 39497755 PMC: 11532903. DOI: 10.12688/hrbopenres.13841.2.

Are All Gay Men at Risk of Developing HIV/AIDS? Why China's Mass HIV Testing Has Majorly Targeted Gay Men in the Era of Biomedicalization.

Yang L, Sun Z Am J Mens Health. 2024; 18(1):15579883241230165.

PMID: 38321807 PMC: 10851740. DOI: 10.1177/15579883241230165.

"What other choices might I have made?": Sexual Minority Men, the PrEP Cascade and the Shifting Subjective Dimensions of HIV Risk.

Gaspar M, Wells A, Hull M, Tan D, Lachowsky N, Grace D Qual Health Res. 2022; 32(8-9):1315-1327.

PMID: 35616240 PMC: 9350448. DOI: 10.1177/10497323221092701.

Community perceptions and acceptability of mass drug administration for the control of neglected tropical diseases in Asia-Pacific countries: A systematic scoping review of qualitative research.

Mitchell E, Kelly-Hanku A, Krentel A, Romani L, Robinson L, Vaz Nery S PLoS Negl Trop Dis. 2022; 16(3):e0010215.

PMID: 35275932 PMC: 8916618. DOI: 10.1371/journal.pntd.0010215.

Discipline for pleasure: a new governmentality of HIV prevention.

Sandset T, Villadsen K, Heggen K, Engebretsen E Biosocieties. 2021; 18(1):102-127.

PMID: 34608399 PMC: 8481318. DOI: 10.1057/s41292-021-00257-1.

References

Mofenson L, McIntyre J . Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet. 2000; 355(9222):2237-44. DOI: 10.1016/S0140-6736(00)02415-6. View

Padian N, McCoy S, Abdool Karim S, Hasen N, Kim J, Bartos M . HIV prevention transformed: the new prevention research agenda. Lancet. 2011; 378(9787):269-78. PMC: 3606928. DOI: 10.1016/S0140-6736(11)60877-5. View

Grulich A, Wilson D . Is antiretroviral therapy modifying the HIV epidemic?. Lancet. 2010; 376(9755):1824. DOI: 10.1016/S0140-6736(10)62162-9. View

Long E, Brandeau M, Owens D . The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010; 153(12):778-89. PMC: 3173812. DOI: 10.7326/0003-4819-153-12-201012210-00004. View

. Trends in HIV prevalence and sexual behaviour among young people aged 15-24 years in countries most affected by HIV. Sex Transm Infect. 2010; 86 Suppl 2:ii72-ii83. PMC: 3173837. DOI: 10.1136/sti.2010.044933. View

Low-Beer D, Stoneburner R . Behaviour and communication change in reducing HIV: is Uganda unique?. Afr J AIDS Res. 2015; 2(1):9-21. DOI: 10.2989/16085906.2003.9626555. View

Padian N, Buve A, Balkus J, Serwadda D, Cates Jr W . Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008; 372(9638):585-99. DOI: 10.1016/S0140-6736(08)60885-5. View

Cohen M, Fidler S . HIV prevention 2010: where are we now and where are we going?. Curr Opin HIV AIDS. 2010; 5(4):265-8. DOI: 10.1097/COH.0b013e32833acafa. View

Halperin D, Mugurungi O, Hallett T, Muchini B, Campbell B, Magure T . A surprising prevention success: why did the HIV epidemic decline in Zimbabwe?. PLoS Med. 2011; 8(2):e1000414. PMC: 3035617. DOI: 10.1371/journal.pmed.1000414. View

10.

Myers G, Mayer K . Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011; 25(2):63-71. DOI: 10.1089/apc.2010.0222. View

11.

Bateman C . Male circumcision roll-out certain - now for 'the how'. S Afr Med J. 2010; 100(2):84-6. View

12.

Medley A, Garcia-Moreno C, McGill S, Maman S . Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ. 2004; 82(4):299-307. PMC: 2585956. View

13.

Bailey R, Moses S, Parker C, Agot K, Maclean I, Krieger J . Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369(9562):643-56. DOI: 10.1016/S0140-6736(07)60312-2. View

14.

Abdool Karim Q, Abdool Karim S, Frohlich J, Grobler A, Baxter C, Mansoor L . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74. PMC: 3001187. DOI: 10.1126/science.1193748. View

15.

Kippax S . Understanding and integrating the structural and biomedical determinants of HIV infection: a way forward for prevention. Curr Opin HIV AIDS. 2009; 3(4):489-94. DOI: 10.1097/COH.0b013e32830136a0. View

16.

Coates T, Richter L, Caceres C . Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008; 372(9639):669-84. PMC: 2702246. DOI: 10.1016/S0140-6736(08)60886-7. View

17.

Dabis F, Newell M, Hirschel B . HIV drugs for treatment, and for prevention. Lancet. 2010; 375(9731):2056-7. DOI: 10.1016/S0140-6736(10)60838-0. View

18.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

19.

Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

20.

Padian N, McCoy S, Balkus J, Wasserheit J . Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010; 24(5):621-35. PMC: 3695696. DOI: 10.1097/QAD.0b013e328337798a. View